Skip to main content
Top
Published in: Journal of Translational Medicine 1/2011

Open Access 01-12-2011 | Methodology

Generation of high-titer viral preparations by concentration using successive rounds of ultracentrifugation

Authors: Christine V Ichim, Richard A Wells

Published in: Journal of Translational Medicine | Issue 1/2011

Login to get access

Abstract

Background

Viral vectors provide a method of stably introducing exogenous DNA into cells that are not easily transfectable allowing for the ectopic expression or silencing of genes for therapeutic or experimental purposes. However, some cell types, in particular bone marrow cells, dendritic cells and neurons are difficult to transduce with viral vectors. Successful transduction of such cells requires preparation of highly concentrated viral stocks, which permit a high virus concentration and multiplicity of infection (MOI) during transduction. Pseudotyping with the vesicular stomatitis virus G (VSV-G) envelope protein is common practice for both lentiviral and retroviral vectors. The VSV-G glycoprotein adds physical stability to retroviral particles, allowing concentration of virus by high-speed ultracentrifugation. Here we describe a method report for concentration of virus from large volumes of culture supernatant by means of successive rounds of ultracentrifugation into the same ultracentrifuge tube.

Method

Stable retrovirus producer cell lines were generated and large volumes of virus-containing supernatant were produced. We then tested the transduction ability of virus following varying rounds of concentration by ultra-centrifugation. In a second series of experiments lentivirus-containing supernatant was produced by transient transfection of 297T/17 cells and again we tested the transduction ability of virus following multiple rounds of ultra-centrifugation.

Results

We report being able to centrifuge VSV-G coated retrovirus for as many as four rounds of ultracentrifugation while observing an additive increase in viral titer. Even after four rounds of ultracentrifugation we did not reach a plateau in viral titer relative to viral supernatant concentrated to indicate that we had reached the maximum tolerated centrifugation time, implying that it may be possible to centrifuge VSV-G coated retrovirus even further should it be necessary to achieve yet higher titers for specific applications. We further report that VSV-G coated lentiviral particles may also be concentrated by successive rounds of ultracentrifugation (in this case four rounds) with minimal loss of transduction efficiency.

Conclusion

This method of concentrating virus has allowed us to generate virus of sufficient titers to transduce bone marrow cells with both retrovirus and lentivirus, including virus carrying shRNA constructs.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hacein-Bey-Abina S, Hauer J, Lim A, Picard C, Wang GP, Berry CC, Martinache C, Rieux-Laucat F, Latour S, Belohradsky BH: Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 363: 355-364. Hacein-Bey-Abina S, Hauer J, Lim A, Picard C, Wang GP, Berry CC, Martinache C, Rieux-Laucat F, Latour S, Belohradsky BH: Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 363: 355-364.
2.
go back to reference Gaspar HB, Parsley KL, Howe S, King D, Gilmour KC, Sinclair J, Brouns G, Schmidt M, Von Kalle C, Barington T: Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet. 2004, 364: 2181-2187. 10.1016/S0140-6736(04)17590-9.CrossRefPubMed Gaspar HB, Parsley KL, Howe S, King D, Gilmour KC, Sinclair J, Brouns G, Schmidt M, Von Kalle C, Barington T: Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet. 2004, 364: 2181-2187. 10.1016/S0140-6736(04)17590-9.CrossRefPubMed
3.
go back to reference Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova JL: Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000, 288: 669-672. 10.1126/science.288.5466.669.CrossRefPubMed Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova JL: Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000, 288: 669-672. 10.1126/science.288.5466.669.CrossRefPubMed
4.
go back to reference Miyoshi H, Smith KA, Mosier DE, Verma IM, Torbett BE: Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science. 1999, 283: 682-686. 10.1126/science.283.5402.682.CrossRefPubMed Miyoshi H, Smith KA, Mosier DE, Verma IM, Torbett BE: Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science. 1999, 283: 682-686. 10.1126/science.283.5402.682.CrossRefPubMed
5.
go back to reference Case SS, Price MA, Jordan CT, Yu XJ, Wang L, Bauer G, Haas DL, Xu D, Stripecke R, Naldini L: Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors. Proc Natl Acad Sci USA. 1999, 96: 2988-2993. 10.1073/pnas.96.6.2988.PubMedCentralCrossRefPubMed Case SS, Price MA, Jordan CT, Yu XJ, Wang L, Bauer G, Haas DL, Xu D, Stripecke R, Naldini L: Stable transduction of quiescent CD34(+)CD38(-) human hematopoietic cells by HIV-1-based lentiviral vectors. Proc Natl Acad Sci USA. 1999, 96: 2988-2993. 10.1073/pnas.96.6.2988.PubMedCentralCrossRefPubMed
6.
go back to reference Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D: In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996, 272: 263-267. 10.1126/science.272.5259.263.CrossRefPubMed Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D: In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996, 272: 263-267. 10.1126/science.272.5259.263.CrossRefPubMed
7.
go back to reference Burns JC, Friedmann T, Driever W, Burrascano M, Yee JK: Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci USA. 1993, 90: 8033-8037. 10.1073/pnas.90.17.8033.PubMedCentralCrossRefPubMed Burns JC, Friedmann T, Driever W, Burrascano M, Yee JK: Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci USA. 1993, 90: 8033-8037. 10.1073/pnas.90.17.8033.PubMedCentralCrossRefPubMed
8.
go back to reference Akkina RK, Walton RM, Chen ML, Li QX, Planelles V, Chen IS: High-efficiency gene transfer into CD34+ cells with a human immunodeficiency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G. J Virol. 1996, 70: 2581-2585.PubMedCentralPubMed Akkina RK, Walton RM, Chen ML, Li QX, Planelles V, Chen IS: High-efficiency gene transfer into CD34+ cells with a human immunodeficiency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G. J Virol. 1996, 70: 2581-2585.PubMedCentralPubMed
9.
go back to reference Mastromarino P, Conti C, Goldoni P, Hauttecoeur B, Orsi N: Characterization of membrane components of the erythrocyte involved in vesicular stomatitis virus attachment and fusion at acidic pH. J Gen Virol. 1987, 68 (Pt 9): 2359-2369.CrossRefPubMed Mastromarino P, Conti C, Goldoni P, Hauttecoeur B, Orsi N: Characterization of membrane components of the erythrocyte involved in vesicular stomatitis virus attachment and fusion at acidic pH. J Gen Virol. 1987, 68 (Pt 9): 2359-2369.CrossRefPubMed
11.
go back to reference Poluri A, Sutton RE: Titers of HIV-based vectors encoding shRNAs are reduced by a dicer-dependent mechanism. Mol Ther. 2008, 16: 378-386. 10.1038/sj.mt.6300370.CrossRefPubMed Poluri A, Sutton RE: Titers of HIV-based vectors encoding shRNAs are reduced by a dicer-dependent mechanism. Mol Ther. 2008, 16: 378-386. 10.1038/sj.mt.6300370.CrossRefPubMed
12.
go back to reference Ory DS, Neugeboren BA, Mulligan RC: A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc Natl Acad Sci USA. 1996, 93: 11400-11406. 10.1073/pnas.93.21.11400.PubMedCentralCrossRefPubMed Ory DS, Neugeboren BA, Mulligan RC: A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc Natl Acad Sci USA. 1996, 93: 11400-11406. 10.1073/pnas.93.21.11400.PubMedCentralCrossRefPubMed
13.
go back to reference Rebel VI, Tanaka M, Lee JS, Hartnett S, Pulsipher M, Nathan DG, Mulligan RC, Sieff CA: One-day ex vivo culture allows effective gene transfer into human nonobese diabetic/severe combined immune-deficient repopulating cells using high-titer vesicular stomatitis virus G protein pseudotyped retrovirus. Blood. 1999, 93: 2217-2224.PubMed Rebel VI, Tanaka M, Lee JS, Hartnett S, Pulsipher M, Nathan DG, Mulligan RC, Sieff CA: One-day ex vivo culture allows effective gene transfer into human nonobese diabetic/severe combined immune-deficient repopulating cells using high-titer vesicular stomatitis virus G protein pseudotyped retrovirus. Blood. 1999, 93: 2217-2224.PubMed
14.
go back to reference Kamel-Reid S, Zhang T, Wells RA: Expression of NPM-RARalpha fusion gene in hematopoietic cells confers sensitivity to troglitazone-induced apoptosis. Oncogene. 2003, 22: 6424-6435. 10.1038/sj.onc.1206696.CrossRefPubMed Kamel-Reid S, Zhang T, Wells RA: Expression of NPM-RARalpha fusion gene in hematopoietic cells confers sensitivity to troglitazone-induced apoptosis. Oncogene. 2003, 22: 6424-6435. 10.1038/sj.onc.1206696.CrossRefPubMed
15.
go back to reference Ichim CV, Atkins HL, Iscove NN, Wells RA: Identification of a role for the nuclear receptor EAR-2 in the maintenance of clonogenic status within the leukemia cell hierarchy. Leukemia. Ichim CV, Atkins HL, Iscove NN, Wells RA: Identification of a role for the nuclear receptor EAR-2 in the maintenance of clonogenic status within the leukemia cell hierarchy. Leukemia.
16.
go back to reference Yamada K, McCarty DM, Madden VJ, Walsh CE: Lentivirus vector purification using anion exchange HPLC leads to improved gene transfer. Biotechniques. 2003, 34: 1074-1078. 1080PubMed Yamada K, McCarty DM, Madden VJ, Walsh CE: Lentivirus vector purification using anion exchange HPLC leads to improved gene transfer. Biotechniques. 2003, 34: 1074-1078. 1080PubMed
17.
go back to reference Reiser J: Production and concentration of pseudotyped HIV-1-based gene transfer vectors. Gene Ther. 2000, 7: 910-913. 10.1038/sj.gt.3301188.CrossRefPubMed Reiser J: Production and concentration of pseudotyped HIV-1-based gene transfer vectors. Gene Ther. 2000, 7: 910-913. 10.1038/sj.gt.3301188.CrossRefPubMed
Metadata
Title
Generation of high-titer viral preparations by concentration using successive rounds of ultracentrifugation
Authors
Christine V Ichim
Richard A Wells
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2011
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-9-137

Other articles of this Issue 1/2011

Journal of Translational Medicine 1/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.